Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HME1 Pictilisib
1.0
pan PI3K
PI3K/mTOR
 0.7247 0.00244
HME1 Pictilisib
3.1623
pan PI3K
PI3K/mTOR
 0.4899 0.01330
HME1 Pictilisib
10.0
pan PI3K
PI3K/mTOR
 0.1260 0.06898
HME1 Ceritinib
0.001
ALK
RTK
 1.0773 -0.00102
HME1 Ceritinib
0.0031623
ALK
RTK
 1.1181 0.00704
HME1 Ceritinib
0.01
ALK
RTK
 1.0833 -0.00303
HME1 Ceritinib
0.031623
ALK
RTK
 1.0787 0.00040
HME1 Ceritinib
0.1
ALK
RTK
 1.0294 -0.00181
HME1 Ceritinib
0.31623
ALK
RTK
 0.8599 -0.00003
HME1 Ceritinib
1.0
ALK
RTK
 0.3827 0.03136
HME1 Ceritinib
3.1623
ALK
RTK
 -0.1977 0.41511
HME1 Ceritinib
10.0
ALK
RTK
 -0.3557 0.69776
HME1 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0755 -0.00110
HME1 Neratinib
0.001
EGFR/HER2
RTK
 1.0978 0.00071
HME1 Neratinib
0.0031623
EGFR/HER2
RTK
 1.0914 -0.00014
HME1 Neratinib
0.01
EGFR/HER2
RTK
 1.0381 -0.00318
HME1 Neratinib
0.031623
EGFR/HER2
RTK
 0.8819 -0.00280
HME1 Neratinib
0.1
EGFR/HER2
RTK
 0.5790 0.00256
HME1 Neratinib
0.31623
EGFR/HER2
RTK
 0.3490 0.01681
HME1 Neratinib
1.0
EGFR/HER2
RTK
 0.2598 0.02873
HME1 Neratinib
3.1623
EGFR/HER2
RTK
 0.0983 0.10757
HME1 Tivantinib
0.001
MET
RTK
 1.0760 -0.00172
HME1 Tivantinib
0.0031623
MET
RTK
 1.1214 0.00739
HME1 Tivantinib
0.01
MET
RTK
 1.0514 0.00596
HME1 Tivantinib
0.031623
MET
RTK
 0.5163 0.12831